NSE · INVICTA
Invicta Diagnostic Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹33 Cr with net profit ₹5 Cr — a 14.85% net margin, versus 16.21% the period before.
Shareholding
As of 2026-03-31
- Promoter66.7%
- Public24.81%
- FII4.2%
- DII4.3%
411 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.81× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 85 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,27,048 Cr | 60.38 | 13.42 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,01,000 Cr | 67.47 | 9.4 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹94,359 Cr | 100.61 | 5.73 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹67,025 Cr | 62.83 | 6.77 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,652 Cr | 171.83 | 15.81 | 8.48% | 6.54% |
| Global Health Limited | ₹38,911 Cr | 67.98 | 9.82 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹38,199 Cr | 44.31 | 8.41 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹32,296 Cr | 154.72 | 8.62 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,042 Cr | 56.97 | 12.78 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,613 Cr | 55.04 | 5.67 | 10.37% | 15.77% |
| Invicta Diagnostic Ltd.(this company) | — | 15.45 | 1.74 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashInvicta Diagnostic Ltd. (INVICTA) operates in the Healthcare sector. As of March 31, 2026, promoters held 66.6953% of the company. The company reported a 276.45% revenue growth.
Positives
- +Revenue grew significantly by 276.45%.
- +Return on Capital Employed (ROCE) is healthy at 43.55%.
- +The debt-to-equity ratio is low at 0.12.
- +Promoter shareholding is substantial at 66.6953% as of March 31, 2026.
- +No promoter shares are pledged, with a pledge percentage of 0%.
Negatives
- −The company has not disclosed quarterly results.
- −No dividend yield is available for the company.
- −The profit margin is not available for assessment.
- −The company is currently under ESM Stage 1 surveillance.
Financial Performance
Invicta Diagnostic Ltd. experienced significant revenue growth, which increased by 276.45%. Revenue rose from Rs 8.3434 Cr in Mar 2024 to Rs 30.6646 Cr in Mar 2025. Net profit also increased from Rs 2.6891 Cr in Mar 2024 to Rs 4.6914 Cr in Mar 2025. Earnings Per Share (EPS) for Mar 2025 stood at Rs 5.57.
Profitability & Returns
The company reported a Return on Capital Employed (ROCE) of 43.55%. The Earnings Per Share (EPS) for the most recent period available is Rs 4.4. No Return on Equity (ROE) figure is available for evaluation.
Balance Sheet
Invicta Diagnostic Ltd. has a low debt-to-equity ratio of 0.12, indicating limited reliance on borrowed capital. The book value per share is Rs 39.05.
Ownership & Pledges
As of March 31, 2026, the promoter shareholding stood at 66.6953%. FIIs held 4.1998% and DIIs held 4.2985%. Public shareholding was 24.8064%. There were no promoter share pledges reported for the latest period, with promoter pledge at 0%.
Regulatory & Surveillance
Invicta Diagnostic Ltd. is currently under the Exchange Surveillance Measure (ESM) framework, specifically ESM Stage 1. This indicates that the stock is subject to enhanced monitoring by the exchange.
Data as of — price: 2026-09-12 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.